All In Biotech

Free tool

FAERS Monitor: Poteligeo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761051 or its brand name (Poteligeo, Mogamulizumab-Kpkc). Reports on generic versions are filed under their own applications.

Reports

1,361

Serious

819

60% of reports

Hospitalization

240

Death reported

198

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • rash193
  • disease progression123
  • drug eruption81
  • pruritus68
  • infusion related reaction59
  • death55
  • pyrexia52
  • fatigue49
  • inappropriate schedule of product administration42
  • chills41
  • drug ineffective37
  • erythema36
  • lymphopenia34
  • nausea34
  • off label use33

Reports by year received

View as table
YearReports
20121
20131
20142
20152
20163
20173
201822
2019210
2020179
2021223
2022227
2023109
2024134
2025125
2026120

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,798 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug eruptionSignal8171.057.45,496
lymphopeniaSignal3437.226.71,161
disease progressionSignal12316.113.61,732
infusion related reactionSignal5913.810.7687
rashSignal1936.86.0977
chillsSignal415.44.0144
inappropriate schedule of product administrationSignal423.62.777
pruritusSignal682.72.274
erythemaSignal362.72.037
pyrexiaSignal522.31.838
death551.00.80
fatigue491.00.70
nausea340.70.56
off label use330.60.410
drug ineffective370.40.329

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.